60 Degrees Pharmaceuticals (SCTP) Q2 2026 earnings summary

Executive summary

• Achieved 106% year-over-year increase in Q2 product revenue, driven by higher shipments to logistics partners and resolution of prior supply shortages.

• Gross margin declined to 27.3% from 50.4% due to higher costs and product mix changes.

• Operating expenses rose 25% year-over-year, mainly from increased R&D and higher sales and promotion costs.

• Net loss for Q2 was $2.26 million, with a six-month net loss of $4.35 million.

• Company remains focused on commercialization of Arakoda and advancing babesiosis clinical trials.

Financial highlights

• Q2 2026 product revenue: $207,898 (up from $100,932 in Q2 2025).

• Gross profit: $56,798 (Q2 2026), up from $50,881 (Q2 2025).

• Gross margin: 27.3% (Q2 2026) vs. 50.4% (Q2 2025).

• Operating expenses: $2.33 million (Q2 2026), up from $1.86 million (Q2 2025).

• Net loss attributable to shareholders: $2.26 million (Q2 2026), $4.35 million (six months).

• Cash and equivalents: $1.02 million as of June 30, 2026.

Outlook and guidance

• Management projects sufficient funds to operate through early October 2026, factoring in July PIPE proceeds.

• Substantial doubt remains about ability to continue as a going concern beyond that period without additional capital.

• Plans include seeking further equity financing and business development transactions.